Fusion Family Wealth’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Fusion Family Wealth’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-685	Closed	-$1K	–	107
2020 Q4	$1K	Hold	685	–	–	﹤0.01%	99
2020 Q3	$2K	Hold	685	–	–	﹤0.01%	98
2020 Q2	$2K	Hold	685	–	–	﹤0.01%	106
2020 Q1	$3K	Hold	685	–	–	﹤0.01%	113
2019 Q4	$2K	Buy	+685	New	+$1.78K	﹤0.01%	128

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Fusion Family Wealth's BMY.RT Position: Q1 2021 in Review

Fusion Family Wealth sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 685 shares — an estimated $1K sold.

Fusion Family Wealth first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $3K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Fusion Family Wealth reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Fusion Family Wealth sold 685 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1K.
Fusion Family Wealth first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Fusion Family Wealth's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Fusion Family Wealth's 13F filing for Q1 2021, filed 29 Apr 2021.